Compare Gilead Sciences, Inc. (GILD) vs Genuine Parts Company (GPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Genuine Parts Company — how do they compare? Gilead Sciences, Inc. trades at $133.61 (market cap $163.51B), while Genuine Parts Company trades at $125.23 (market cap $16.65B). The key difference: Gilead Sciences, Inc. is far larger — about 9.8× Genuine Parts Company's market cap, and Genuine Parts Company pays the higher dividend (3.51%). Which is the better fit depends on your goals.
| GILD | GPC | |
|---|---|---|
Market Cap | $163.51B | $16.65B |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $149.26 |
52-Week Low | $108.22 | $92.47 |
Enterprise Value | $178.05B | $22.87B |
Dividend Yield | 2.49% | 3.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Genuine Parts Company (GPC) trades at $122.16, down 1.1% on the day, with a bullish technical signal supported by moving averages and oscillators. Fundamentally, the company shows strong revenue growth to $24.3B in 2025 but faces significant margin compression, with net income plummeting to $66M (0.27% margin) from $904M the prior year. The stock carries a high P/E of 275 but reasonable P/S of 0.68, while analysts maintain a consensus 'Buy' rating with a $133 price target. Recent news highlights GPC's upcoming Q2 2026 earnings report on July 21, 2026, and its status as a Dividend King with 70 consecutive years of dividend increases.
The outlook presents a mixed picture: technical strength and dividend reliability support the stock, while deteriorating profitability and high valuation multiples pose significant risks. Investment opportunity lies in potential earnings recovery and continued dividend growth, but investors face headwinds from margin pressure and elevated P/E ratio requiring careful monitoring of upcoming quarterly results.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Genuine Parts Company
Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →
